FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2142586136> ?p ?o ?g. }

• W2142586136 endingPage "1014" @default.
• W2142586136 startingPage "1006" @default.
• W2142586136 abstract "Background: The RET proto-oncogene encodes a receptor tyrosine kinase. RET oncogenes arise through sporadic and inherited gene mutations and are involved in the etiopathogenesis of medullary thyroid carcinoma, a cancer that responds poorly to conventional chemotherapy. Medullary thyroid carcinoma is a component of multiple endocrine neoplasia type 2 or MEN2 syndromes. Methods: We investigated the cellular effects of RPI-1, a novel 2-indolinone Ret tyrosine kinase inhibitor on cells that express RET C634 oncogenic mutants common in the MEN2A syndrome: NIH3T3 fibroblasts transfected with RET C634R and human medullary thyroid carcinoma TT cells that express endogenous RET C634W . RPI-1 antiproliferative activity was determined by cell proliferation and anchorage-independent growth assays. Expression and phosphorylation of Ret and of proteins involved in downstream signaling pathways were examined by immunoblotting. Antitumor activity of oral RPI-1 treatment was tested by using two dosing levels in nude mice bearing subcutaneous TT xenograft tumors. All statistical tests were two-sided. Results: The RPI-1 IC 50 value for cell proliferation was 3.6 μ M (95% confidence interval [CI] = 1.8 to 5.4 μ M ) in NIH3T3 cells expressing the Ret mutant compared with 16 μ M (95% CI = 12.3 to 19.7 μ M ) in non-transfected NIH3T3 cells, and that for colony formation in soft agar was 2.4 μ M (95% CI = 0.8 to 4.0 μ M ) and 26 μ M (95% CI = 17 to 35 μ M ) in RET mutant–transfected and H-RAS-transfected NIH3T3 cells, respectively. In NIH3T3 cells expressing the Ret mutant, Ret protein and tyrosine phosphorylation were undetectable after 24 hours of RPI-1 treatment. In TT cells, RPI-1 inhibited proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCγ, ERKs and AKT. In mice, oral daily RPI-1 treatment inhibited the tumor growth of TT xenografts by 81% ( P <.001 versus control mice) and reduced the plasma levels of the specific biomarker calcitonin ( P = .01 versus control mice). Twenty-five percent of RPI-1-treated mice were tumor-free. Conclusions: Ret oncoproteins represent exploitable targets for therapeutic intervention in MEN2A-associated medullary thyroid carcinoma. The antitumor efficacy and oral bioavailability of RPI-1 support its therapeutic potential." @default.
• W2142586136 created "2016-06-24" @default.
• W2142586136 creator A5016297492 @default.
• W2142586136 creator A5028847995 @default.
• W2142586136 creator A5033312783 @default.
• W2142586136 creator A5034214221 @default.
• W2142586136 creator A5050566824 @default.
• W2142586136 creator A5054112956 @default.
• W2142586136 creator A5056273091 @default.
• W2142586136 creator A5063791104 @default.
• W2142586136 creator A5064897676 @default.
• W2142586136 creator A5078976916 @default.
• W2142586136 creator A5089447283 @default.
• W2142586136 date "2004-07-06" @default.
• W2142586136 modified "2023-10-18" @default.
• W2142586136 title "Cellular Effects and Antitumor Activity of RET Inhibitor RPI-1 on MEN2A-Associated Medullary Thyroid Carcinoma" @default.
• W2142586136 cites W1787102412 @default.
• W2142586136 cites W1804131072 @default.
• W2142586136 cites W1979517834 @default.
• W2142586136 cites W2000347396 @default.
• W2142586136 cites W2024811932 @default.
• W2142586136 cites W2032457962 @default.
• W2142586136 cites W2038095897 @default.
• W2142586136 cites W2050216630 @default.
• W2142586136 cites W2057936106 @default.
• W2142586136 cites W2064505617 @default.
• W2142586136 cites W2065432648 @default.
• W2142586136 cites W2069398477 @default.
• W2142586136 cites W2071749936 @default.
• W2142586136 cites W2073051869 @default.
• W2142586136 cites W2074306827 @default.
• W2142586136 cites W2079244398 @default.
• W2142586136 cites W2092436145 @default.
• W2142586136 cites W2104800170 @default.
• W2142586136 cites W2109689528 @default.
• W2142586136 cites W2113211220 @default.
• W2142586136 cites W2113242315 @default.
• W2142586136 cites W2170416930 @default.
• W2142586136 cites W2260407561 @default.
• W2142586136 cites W2322651575 @default.
• W2142586136 cites W2323500245 @default.
• W2142586136 cites W2326198834 @default.
• W2142586136 cites W2329619823 @default.
• W2142586136 cites W2479044294 @default.
• W2142586136 cites W4240149091 @default.
• W2142586136 doi "https://doi.org/10.1093/jnci/djh184" @default.
• W2142586136 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15240784" @default.
• W2142586136 hasPublicationYear "2004" @default.
• W2142586136 type Work @default.
• W2142586136 sameAs 2142586136 @default.
• W2142586136 citedByCount "108" @default.
• W2142586136 countsByYear W21425861362012 @default.
• W2142586136 countsByYear W21425861362013 @default.
• W2142586136 countsByYear W21425861362014 @default.
• W2142586136 countsByYear W21425861362015 @default.
• W2142586136 countsByYear W21425861362016 @default.
• W2142586136 countsByYear W21425861362017 @default.
• W2142586136 countsByYear W21425861362018 @default.
• W2142586136 countsByYear W21425861362019 @default.
• W2142586136 countsByYear W21425861362020 @default.
• W2142586136 countsByYear W21425861362021 @default.
• W2142586136 countsByYear W21425861362022 @default.
• W2142586136 countsByYear W21425861362023 @default.
• W2142586136 crossrefType "journal-article" @default.
• W2142586136 hasAuthorship W2142586136A5016297492 @default.
• W2142586136 hasAuthorship W2142586136A5028847995 @default.
• W2142586136 hasAuthorship W2142586136A5033312783 @default.
• W2142586136 hasAuthorship W2142586136A5034214221 @default.
• W2142586136 hasAuthorship W2142586136A5050566824 @default.
• W2142586136 hasAuthorship W2142586136A5054112956 @default.
• W2142586136 hasAuthorship W2142586136A5056273091 @default.
• W2142586136 hasAuthorship W2142586136A5063791104 @default.
• W2142586136 hasAuthorship W2142586136A5064897676 @default.
• W2142586136 hasAuthorship W2142586136A5078976916 @default.
• W2142586136 hasAuthorship W2142586136A5089447283 @default.
• W2142586136 hasBestOaLocation W21425861361 @default.
• W2142586136 hasConcept C101544691 @default.
• W2142586136 hasConcept C104317684 @default.
• W2142586136 hasConcept C121608353 @default.
• W2142586136 hasConcept C126322002 @default.
• W2142586136 hasConcept C134018914 @default.
• W2142586136 hasConcept C13514818 @default.
• W2142586136 hasConcept C170493617 @default.
• W2142586136 hasConcept C2776512331 @default.
• W2142586136 hasConcept C2776667971 @default.
• W2142586136 hasConcept C2778820342 @default.
• W2142586136 hasConcept C2779761222 @default.
• W2142586136 hasConcept C2780120053 @default.
• W2142586136 hasConcept C2993294228 @default.
• W2142586136 hasConcept C42362537 @default.
• W2142586136 hasConcept C501734568 @default.
• W2142586136 hasConcept C502942594 @default.
• W2142586136 hasConcept C526584372 @default.
• W2142586136 hasConcept C54009773 @default.
• W2142586136 hasConcept C54355233 @default.
• W2142586136 hasConcept C55493867 @default.
• W2142586136 hasConcept C62112901 @default.
• W2142586136 hasConcept C71924100 @default.

• next